In the constant search to improve the Breast cancer detection and treatmenthe Maimonides Institute for Biomedical Research of Cordoba (IMIBIC) has launched groundbreaking research that could change the landscape for breastfeeding mothers.
Under the name of HERA Projectthis initiative, led by the IMIBIC New Cancer Therapies Group, is focused on identifying biomarkers in breast milk that allow for a early diagnosis of postpartum breast cancer (PPCM)a subtype of cancer that has been shown to be especially aggressive.
HOW TO PARTICIPATE BY DONATING MILK
To date, Breast milk samples have been collected from more than 800 women in several collection centres in Córdoba. However, to achieve the objective of the studyat least 2,000 breast milk donations are needed.
Nursing mothers interested in contributing to this essential research can donate their breast milk. To do so, they can: Request your appointment through the official website of the HERA ProjectYour participation is crucial to advance this fight and protect the health of future generations.
Until now you could only donate in Córdoba, but starting in September Donation points will be expanded to different locations in Andalusia.
Space reserved for the video player
60% OF DIAGNOSED CASES ARE IN WOMEN UNDER 45 YEARS OLD
Postpartum breast cancer is a form of cancer that is diagnosed up to ten years after childbirth. Although its classification as a separate category is relatively recent, studies carried out in Córdoba reveal an alarming statistic: this type of cancer represents 60% of cases diagnosed in women under 45 years of age. In terms of numbers, this translates into between 80 and 100 new cases per year in the province of Córdoba, which has a population of approximately 700,000 inhabitants.
It is increase in the incidence of CMPP is attributed to various factorsincluding a delay in the age of first pregnancy and changes in lifestyle. Research suggests that Women who have their first child after the age of 35 face a higher risk of developing this type of cancer. compared to those who give birth at earlier ages.
COMPLEX DETECTION
Early diagnosis of postpartum breast cancer is essential, since This subtype has a more aggressive prognosis than others.. However, Detection is complex due to the hormonal and physiological changes that occur during and after pregnancy. These changes not only affect the development of cancer, but also the effectiveness of conventional diagnostic methods.
Although epidemiological evidence has allowed us to identify some risk factors, the exact molecular mechanisms that cause this type of cancer are still not fully understood. This is where the HERA project, which aims to discover molecular indicators in breast milk that can signal the presence of cancer early.
INNOVATION FROM CÓRDOBA
The HERA Project represents a milestone in oncology researchTaking advantage of the rich composition of breast milk, which contains a wide variety of biomolecules, IMIBIC researchers seek to identify cellular changes that could indicate the early development of cancer. This approach could not only revolutionize CMPP detection, but also would allow for the identification of women at greatest riskopening the door to personalized treatments that significantly improve survival rates.
This is not just a scientific initiative, but a community effort. The research is supported by the Carlos III Health Institute, co-financed by the European Union, and the Andalusian Society of Medical Oncology (SAOM). In addition, numerous local associations and groups, such as the Milk Bank of Córdoba and Almamar, are actively collaborating to encourage the participation of breastfeeding mothers.
The commitment of the scientific community and mothers of Cordoba reflects the importance of this project for the city. In addition, companies and other initiatives have contributed financially, which has allowed this research to advance solidly.
PROMISING FUTURE AGAINST POSTPARTUM BREAST CANCER
Postpartum breast cancer is a growing challenge that requires specific attention and dedicated resources for research. Thanks to innovative projects such as HERA, led by IMIBIC, Córdoba is at the forefront of the fight against this type of cancerCollaboration between researchers, healthcare professionals and society is crucial to generate the necessary knowledge to design new prevention, diagnosis and treatment strategies.
Project HERA not only offers hope to breastfeeding mothers, but also lays the groundwork for a future in which postpartum breast cancer can be detected early, significantly improving treatment options and ultimately, saving lives.
